Purpose: The goal of the study was to investigate a method for the real-time assessment of a target concentration in vivo using a combination of a spectral unmixing technique and a fluorescent probe specific for amyloid beta (Aβ) species, the biomarkers for Alzheimer's disease (AD). Procedures: The probe CRANAD-3 has a significant emission wavelength shift upon binding to Aβ species. It was used to differentiate a bound probe from an unbound probe in a phantom, ex vivo in brain slices and whole brain, and in vivo in a transgenic mouse model of AD. Results: The ex vivo unmixing imaging of AD brain clearly showed differential distribution of the bound and unbound probes between the brain tissue and blood vessels. The in vivo unmixed signals of bound CRANAD-3 reached a plateau with increasing dosage, demonstrating that these signals correspond to Aβ content, not probe injected dose. Conclusion: This study provided evidence that signals processed by the spectral unmixing technique could be used as a real-time reporter of Aβ species loading in vivo and ex vivo.
Introduction

D
ifferentiation of bound and unbound fluorescence probes in vivo is an immense challenge in imaging research. Normally, quantification of the signal of a bound probe is conducted after washing out any unbound, free probe. However, this washout step may result in the unintentional clearance of a certain fraction of the bound probe, resulting in an underestimation of the true concentration of the target. To produce a real-time report of a target concentration in vivo, we propose a method that combines a spectral unmixing technique [1] [2] [3] [4] [5] with the application of a wavelength-responsive fluorescent probe [6] [7] [8] [9] . The wavelength-responsive probe's fluorescent spectrum is distinct in its bound and unbound states, thereby enabling the potential use of spectral unmixing techniques to resolve raw image signal into individual spectra corresponding to background, bound probe, and free probe signals.
Spectral unmixing, a dissecting algorithm, is able to partition crude fluorescence signals originated from multiple fluorophores into individual contributors. Although spectral unmixing is widely used in fluorescence microscopy for cell imaging [4, 5, 10] , its in vivo applications are technically challenging. Tissue absorption and scattering can have a significant impact on the measured spectrum of a fluorophore, making the in vivo spectrum considerably different from that in vitro. In in vitro microscopy imaging, signals from fluorophores are diluted in a thin transparent solution or collected directly from a very thin focus plane. Therefore, microscopic imaging could be considered a 2D imaging. In in vivo imaging, however, scattering tissue contributes to a cloud of pixels surrounding fluorophore signals that are delivered as diffuse radiance. Therefore, in vivo imaging could be considered as a complex 3D problem. Recently, Xu and Rice [1] showed that a multivariate curve resolution (MCR) method could be used as a spectral unmixing algorithm for in vivo optical imaging that does not rely on precharacterized spectral libraries. More importantly, their MCR algorithm could solve the complex 3D approximation using the measured 2D spectral data. They have successfully demonstrated the technique by unmixing autofluorescence and two different fluorescent probes in nude mice.
We have previously reported that several curcumin-based near-infrared fluorescence probes were "turn on" probes for amyloid beta (Aβ) species [7, 11] , the most important biomarkers for diagnosis of Alzheimer's disease (AD) [12, 13] . Probe binding to Aβ species led to significant changes in several fluorescent properties, including fluorescence intensity, emission peak, lifetime, and quantum yield. In this study, we utilized the emission wavelength change of curcumin probe and spectral unmixing techniques to distinguish between the spectra of the bound and unbound probes upon binding to the target. We believe that this method provides a way to perform a real-time assessment of Aβ species in vivo.
Methods
The reagents used for synthesis were purchased from Aldrich and used without further purification. Column chromatography was performed on silica gel (SiliCycle Inc., 60Å, 40-63 mm) slurry packed into glass columns. Synthetic amyloid-β peptide (1-40/42) was purchased from rPeptide (Bogart, GA, 30622). 1 H and 13 C NMR spectra were recorded at 500 and 125 MHz, respectively, and reported in parts per million downfield from tetramethylsilane. Fluorescence studies were carried out using a F-4500 fluorescence spectrophotometer (Hitachi). Transgenic APP-PS1 mice and agematched wild-type mice were purchased from Jackson Laboratory. All experimental procedures were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital. In vivo NIR imaging was performed using the IVIS ® Spectrum animal imaging system (Caliper LifeSciences, Hopkinton, MA), and spectral unmixing was conducted using LivingImage ® 3.2 software.
Synthesis of CRANAD-3
The synthesis of the immediate material (2,2-difluoro-1,3-dioxaboryl-pentadione) was performed using a modified procedure [7] . The immediate compound (0.15 g, 0.1 mmol) was dissolved in acetonitrile (3.0 mL), and acetic acid (0.2 mL), tetrahydroisoquinoline (0.04 mL, 0.3 mmol), and 6-N,N′-diethyl-3-pyridylaldehyde (0.36 g, 2.0 mmol) were added. Phantom Imaging A 1.0 mL phosphate-buffered saline (PBS) solution of Aβ42 (250 nM) was added to each well of a 12-well plate, followed by the addition of a DMSO solution (10 μL) of CRANAD-3. The final concentrations of CRANAD-3 added were 50, 100, 250, 500, 750, and 1,000 nM, with samples prepared in quadruplicate. The resulting plate was subjected to imaging using IVIS ® Spectrum by setting Ex=530 nm, Em=580-840 nm with 14 filters, subject height=0.2 cm, and FOV=C. Spectral unmixing was performed with LivingImage ® 3.2 software by setting component = 3 (representing three fluorophores that include autofluorescence, bound CRANAD-3, and free CRANAD-3), Photo Mask (used for selection of the area of interest), and Auto constraints (used for constraining parameters to allow user zeroing low bandpass and making non-negative contribution from fluorophores. In our experiments, the auto default model from the imaging system was used).
Tissue Staining and Imaging
Wild-type (20-month-old) or APP/PS1 (14-month-old) mouse brain tissue was cut into 25-μm slices, fixed in 4% formalin for 5 min, and washed twice with PBS buffer. The tissue was incubated with 0.01% CRANAD-3 (in 50% ethanol) and washed. The tissue was subjected to imaging using the same parameter settings as were used for the phantom imaging.
Ex Vivo Brain Imaging
A 24-month-old APP/PS1 mouse was intravenously injected with 1.5 mg/kg CRANAD-3 (freshly prepared with 15% DMSO, 15% cremophor, and 70% PBS buffer). After 1 h, the mouse was killed and the brain, heart, and spinal cord were collected. The three tissue/organs were subjected to imaging with Ex= 530 nm, Em=580-840 nm, small binning, f=2, FOV=B, and exposure time=0.5 s. Spectral unmixing was performed using LivingImage ® 3.2 software by setting component=3, Photo Mask, and Auto constraints.
In Vivo Imaging
Imaging was performed using an IVIS® Spectrum optical system. For dosage testing, APP-PS1 mice (n= 3) were shaved and intravenously injected with 0.25, 0.5, 0.75, and 1.0 mg/kg of freshly prepared CRANAD-3 in 15% DMSO, 15% cremophor, and 70% PBS. Fluorescence signals from the brain were recorded at 30 min after the injection of the probe. To monitor the progression of AD pathology (11-and 19-month-old APP-PS1 mice, n=5), image sequences were recorded at 10, 20, 30, 40, and 50 min postinjection. Imaging parameters were set at Ex=570 nm, Em=620-840 nm, medium binning, f=4, FOV=C, and exposure time=1 s. Spectral unmixing was performed with LivingImage ® 3.2 software by setting component=3, Photo Mask, and Auto constraints. To evaluate imaging results, a region of interest (ROI) was drawn around the brain region. For the bound signal, the ROI was drawn on the unmixed image corresponding to the bound spectrum, and total efficiency, which is the fluorescence emission image normalized to the incident excitation intensity (radiance of the subject/illumination intensity), was used for quantification.
Results
Phantom Unmixing Imaging with Synthetic Aβ42 Monomers
CRANAD-3 is a curcumin derivative that displays property changes after binding to Aβ species. In particular, there is a 60-nm blue shift of the emission peak upon binding to synthetic Aβ42 (Fig. 1a) . To demonstrate the proof-ofprinciple that CRANAD-3 could be used together with the spectral unmixing technique, we incubated a fixed concentration of synthetic Aβ42 monomers (250 nM for all the wells) with varied concentrations of CRANAD-3 (50-1000 nM, see "Methods" for details). The plate was imaged using an excitation filter at 535 nm and emission signal in the range of 580-840 nm (raw images are shown in Electronic Supplementary Material (ESM) SI Fig. 1 ). We performed spectral unmixing for this plate to resolve the bound CRANAD-3 and the free CRANAD-3. The unmixed distribution images are shown in Fig. 1b . As seen in Fig. 1c , the two spectra were clearly resolved after unmixing. Furthermore, the spectra of the bound and free CRANAD-3 closely resembled the spectra recorded using a fluorescence spectrophotometer (Fig. 1a) , with the spectrum peak for the bound probe around 640 nm and the spectrum peak for the free probe around 700 nm. The intensity of the unmixed bound signal increased with increasing concentration of CRANAD-3, which ranged from 50 to 250 nM. However, the bound signal did not significantly increase with concentrations of CRANAD-3 ranging from 250 to 1,000 nM. In contrast, the unmixed signal for the free probe increased with all concentrations of CRANAD-3.
Quantifications of the efficiencies of the signals-in which: Efficiency (%)=emission light (photons/s)/excitation light (photons/s)-were conducted at different probe concentrations (Fig. 1d) . Consistent with the unmixed images, the quantified bound signal did not significantly change with increases in probe concentration once Aβ reached a fully bound, saturated state. However, the free probe signal increased with all probe concentrations, suggesting that the unmixed bound signal was tightly correlated with the concentration of Aβ but not with the concentration of the probe added.
Imaging of CRANAD-3-Stained Brain Slice from a Wild-Type Mouse
To test whether the spectral unmixing technique was capable of differentiating the binding status of the probe in brain tissue, we stained a brain slice from a 20-month-old wildtype mouse with no Aβ pathology with CRANAD-3 and then imaged the slice using similar imaging parameters as the phantom imaging. In raw images of the slice, we found that the signal from the corpus callosum, the largest white matter structure of the brain, was slightly higher than in the other regions (Fig. 2a) , suggesting that CRANAD-3 had some interaction with white matter. To test whether the unmixed spectrum for white matter was different from the spectrum of CRANAD-3 bound to Aβ determined from phantom studies, we unmixed the raw images into three components, representing autofluorescence, white matter binding, and free probe spectra. After unmixing, we found that the peak for white matter binding was around 600 nm, a 40-nm difference from that of the Aβ bound spectrum from phantom studies (Figs. 2b and 1c) . This was not surprising given that fluorescence probes are known to display a higher intensity and blue shift upon interaction with hydrophobic environments [14] , like the environment of white matter tissue. We found that the peak for the free probe (680 nm) was 20 nm shorter than that of the phantom (700 nm), a finding likely due to the differences in the environment between phantom solution and brain slices (Fig. 2b) . The distribution map likewise showed that the CRANAD-3 bound to white matter was mostly present in the corpus callosum area (#2 and #4 in Fig. 2c ), while the free probe was distributed randomly across the tissue (#3 in Fig. 2c) . Our results suggest that spectral unmixing coupled with wavelength-responsive probe CRANAD-3 allows us to spectrally and spatially differentiate white matter binding from the free probe while providing evidence that binding to non-Aβ structures can be differentiated from Aβ binding by a spectral peak shift.
Ex Vivo Imaging of a Brain Slice from APP/PS1 Mouse APP/PS1 mice, a widely used transgenic strain for AD research, express chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and mutant human presenilin 1 protein (PS1-dE9). The "humanized" Mo/ HuAPP695swe transgene allows the mice to secrete a human Aβ peptide, leading to a gradual increase in Aβ loading during the aging process [15, 16] . In our next experiment, we used brain slices of a 14-month-old APP/ PS1 transgenic mouse obtained after intravenous injection of CRANAD-3. Interestingly, the raw images of an ex vivo slice showed weak white matter binding (Fig. 3a) , indicating that at the time of imaging (2 h post-injection) most CRANAD-3 had washed out of the white matter. As expected, we obtained well-resolved spectra and images after performing the unmixing procedure (Fig. 3b, c) corresponding to spectral signals of autofluorescence, the Aβ-bound probe, and the free probe. From Fig. 3b , it can be seen that the bound probe primarily distributed to the cortex area and hippocampus, with the distribution pattern similar to the Aβ plaque deposit pattern observed in fluorescent microscopic images (ESM SI Fig. 3 ). The spectrum peak of the bound probe was 640 nm, the same as the peak obtained in phantom imaging studies (Fig. 1c) . Similarly, the spectrum of the free probe was very similar to that of in vitro CRANAD-3-stained wild-type brain slice (Fig. 2b) .
Ex Vivo Imaging of a Whole Brain from APP/PS1 Mouse
After we demonstrated that the spectral unmixing technique was feasible for brain tissue slices using our CRANAD-3 probe, we tested this technique on the whole brain ex vivo. To this end, we obtained the non-perfused whole brain from a 24-month-old APP/PS1 mouse 1 h after intravenous injection of CRANAD-3. The brain, heart, and a portion of the spinal cord were imaged as described previously. After unmixing of the raw images, well-resolved spectra were generated for autofluorescence, the bound, and the unbound CRANAD-3 (Fig. 4a) . The spectra were similar to those obtained after AD tissue imaging. Remarkably, the unmixed images clearly showed that the bound probe was primarily located in the cortex (#2 in Fig. 4b ), while the unbound probe was present in the blood vessels, across the whole brain, and in the heart (#3 in Fig. 4b) . The composite image, the merged/summated picture of the images of the unmixed components, indicated that the probe in the blood vessel and the heart primarily existed in its unbound form (red, #4 in Fig. 4b ), whereas the probe in the cortical regions was bound (blue). Additionally, we noticed that the probe in the spinal cord was mainly present as a bound form (blue), while the blood in the narrow tissue area surrounding the spinal cord contained an unbound probe (red). These unmixed images reflected the fact that Aβ species were primarily present in the cortex and cerebrospinal fluid and that their concentration in the blood was considerably lower. In addition, we did not observe the spectral peak for white matter binding. Several things could account for this, including the deeper location of the white matter, washing out of the probe from the white matter, or the embedding of the white matter binding signal into the spectrum of autofluorescence.
Differentiating Wild-Type and Transgenic AD Mice by Spectral Unmixing In Vivo
The intrinsic difference between wild-type and transgenic AD mice is the absence of Aβ species in the wild type [15, 16] . We reasoned that the free probe would be a dominant component in wild-type mice, while the probe bound to Aβ species would predominate in APP/PS1 mice. To test this hypothesis, we intravenously injected both wild-type and APP/PS1 mice with CRANAD-3 and imaged them with excitation at 570 nm and emission ranging from 620 to 840 nm. We selected the 570-nm filter excitation for in vivo imaging because of its better tissue penetration than 535 nm, the excitation filter for ex vivo imaging. We unmixed the raw images using autofluorescence and unbound free probe as two expected major components in wild-type mouse. There was a peak in the unmixed spectra around 670 nm (Fig. 5a ) corresponding to the free probe existing in an unbound form. The unmixed spectrum for APP/PS1 mouse was very similar to the spectrum of the Aβ-bound probe, suggesting that the major component existed in the bound form (Fig. 5a ). This result indicates that we could use the spectral unmixing technique to differentiate wildtype from transgenic AD mice. Fig. 3 . a Raw image (Em=640 nm) of ex vivo APP/PS1 mouse brain tissue. b Unmixed distribution image of the bound probe. c Unmixed spectra of autofluorescence (green), the bound probe (blue), and the free probe (red). Fig. 4 . a Unmixed spectra of autofluorescence (green), the bound probe (blue), and the free probe (red). b Unmixed distribution images of autofluorescence (#1), bound probe (#2), free probe (#3), and composite (#4).
Real-Time Report of Aβ Loading and Monitoring the Progression of Amyloidosis Pathology in APP/ PS1 Mice
In the phantom imaging experiment, we showed that the unmixed bound probe signal was tightly correlated with the content of Aβ, suggesting that this unmixing technique could be used to report the concentration of a target in real time.
To test the feasibility of this approach in vivo, we injected 16-month-old APP/PS1 mice with different dosages of CRANAD-3 (0.25-1.0 mg/kg) and imaged 30 min postinjection (a representative raw image sequence is shown in ESM SI Fig. 2) . We then unmixed the raw images into the spectra of three components corresponding to autofluorescence, the Aβ-bound probe, and the free probe. As expected, distinct unmixed spectra were obtained for all three components, with the peak for the bound probe at 640 nm and the peak for the free probe at 680 nm (Fig. 6b) . These peaks corresponded well with the results of ex vivo whole brain imaging. A semi-quantitative analysis of the unmixed images was conducted by selecting the whole brain area as a ROI and monitoring total efficiency at 30 min post-injection as the readout. Analysis of the raw images showed that the raw signals at 640 nm increased with increasing dosages of the probe (Fig. 6c, black line) . The unmixed signal for the bound probe increased with increasing the probe dosage from 0.25 to 0.5 mg/kg. However, at dosages of 0.5, 0.75, and 1.0 mg/kg, the unmixed signals were not substantially different (Fig. 6c, red line) . This result indicated that (1) the target Aβ was saturated around the dosage of 0.5 mg/kg and (2) the unmixed signals were closely correlated to the loading of Aβ and independent of injection dosages once the target was saturated. This result was consistent with the results of phantom imaging in which the unmixed Aβ-bound signal was tightly associated with the concentration of Aβ species.
Next, we attempted to image differential Aβ loading in APP/PS1 mice of different age groups (11 and 19 months old) after injection of CRANAD-3 using our approach. Analysis of the unmixed images displayed significant differences in the bound signal between the two groups. The signal from the 19-month-old mice was 1.3-fold higher than that of the 11-month-old mice at 10, 20, and 30 min (Fig. 6d) . As seen in Fig. 6d , the readings at 10, 20, and 30 min were very consistent for both groups, indicating that the target was steadily saturated, while a partial washout of the bound probe could be observed around 40 min. We believe that this saturated state reflects the Aβ loading in vivo. Our results further indicate that it is feasible to use the spectral unmixing technique to monitor the increasing Aβ loading associated with age, thus providing the ability to monitor the disease progression in AD mice.
Discussion
For intensity-based NIR imaging in the absence of a "smart" probe, in vivo differentiation between wild-type and transgenic mice always depends on the retention of the probe, which required significant time [17] . However, a probe with a "smart" property (such as intensity increase upon interaction with the target) could be used to differentiate wild-type and transgenic mice at the very early time points after injection [7] . Yet, the signals from these intensity-based images cannot reflect the real-time concentration of the target since these represent the sum signal from both the bound and the free probes. For wavelength-based imaging, the spectral unmixing technique could be used to resolve multiple components. When this technique was coupled with a probe possessing a significant emission wavelength shift upon binding to a target, it allowed differentiation between the bound and the unbound probe. Therefore, the signal from the bound probe in this case reflects the real-time concentration of the target if the probe saturates the target. In this report, we demonstrated that this technique is not only able to differentiate transgenic and wild-type mice by comparing their unmixed spectra but also able to report the Aβ content in real time once the Aβ was saturated.
Although spectral unmixing techniques have been widely used in microscopic imaging for more than 10 years, their in vivo application in whole organs or the body has just been reported recently [1] . In principle, this technique could allow us to distinguish infinite components that have different spectra; however, in practice, its capacity is limited by the filter bandwidth and simulation method. In this report, we used the emission filter bandwidth of 20 nm such that any spectral differences G20 nm could not be well resolved. For microscopic spectral unmixing, linear unmixing is used, a procedure that is not suitable for in vivo whole body imaging of mice. Recently, Xu and Rice [1] reported that MCR could be used for in vivo spectral unmixing. In this report, we also demonstrated that MCR in combination with a wavelengthresponsive fluorescent probe could be used for in vivo spectral unmixing imaging.
In vivo spectral unmixing techniques are still in an early stage of development. Significant improvements for both imaging hardware and processing software are highly desirable. We believe that better spectral resolution, achieved using continuous emission collection and improved software, will provide a more robust signal separation and more reliable quantification analysis.
In summary, we demonstrated that a spectral unmixing technique in conjunction with wavelength-responsive fluorescent probe CRANAD-3 enabled us to differentiate autofluorescence, the Aβ-bound probe, and the free probe in vitro and in vivo in a mouse model of Alzheimer's disease. The unmixed spectra of the Aβ-bound probe and free probe were in a good accordance in various samples, including phantom solution, in vitro stained slice, ex vivo slice, ex vivo whole brain, and in vivo mice. Furthermore, this method was also able to differentiate between wild-type mice and transgenic AD mice, and the tight correlation between the bound signal and the Aβ content provided a basis for real-time reporting of Aβ load in vivo. Moreover, we showed that with this unmixing technique, we were able to detect the Aβ content changes during the progression of the disease. Finally, we believe that this technique could be extended to other wavelength-responsive probes that display wavelength shift characteristics upon interaction with corresponding substrates [18] [19] [20] .
